Appendix 4E and Annual Report (Form 10-K)

• Revenue increased 11% to $71.6 million
• Gross profit margin was 82.1%
• Net loss decreased 21% to $48.6 million
• Secured $60 million credit facility to fund operations

Avita Medical Inc reported its financial results for the year ended December 31, 2025. Revenue increased 11% to $71.6 million, driven by deeper penetration within customer accounts, new accounts for the treatment of traumatic and surgical wounds, and new product launches. Gross profit margin was 82.1% compared to 85.8% in the prior year, primarily due to product mix and higher inventory reserve. Total operating expenses decreased by 9% to $101.4 million, reflecting lower sales and marketing expenses as well as lower general and administrative expenses. Net loss decreased 21% to $48.6 million compared to the prior year. The company had approximately $10.2 million in cash and cash equivalents and $7.9 million in marketable securities as of December 31, 2025. To fund its operations, the company entered into a $60 million credit facility subsequent to the end of the year. Management has determined there is substantial doubt about the company's ability to continue as a going concern over the next twelve months due to its debt repayment obligations, historical negative cash flows, and recurring losses.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics.

The company did not provide any forward-looking outlook statements.